OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Santos on Exciting Advancements in Field of Lung Cancer

November 22nd 2016

Edgardo S. Santos, MD, medical oncology, internal medicine, Boca Raton Regional Hospital, discusses exciting advancements in the field of lung cancer. Santos shared this insight during the 2016 OncLive State of the Science Summit on Lung Cancer.

Dr. Fonseca on FDA Approval of Daratumumab Triplets in Multiple Myeloma

November 22nd 2016

Rafael Fonseca, MD, professor of Medicine, Mayo Clinic, discuses the recent FDA approval of daratumumab (Darzalex) in combination with lenalidomide and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.

Dr. Shlomo Koyfman on Radiation in Recurrent Head and Neck Cancer

November 22nd 2016

Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses radiation therapy in recurrent head and neck cancer.

Dr. Moreau on Combination Treatments in Multiple Myeloma

November 22nd 2016

Philippe Moreau, MD, head of the Hematology Department, University Hospital of Nantes, France, discusses the combination treatments being used to treat patients with multiple myeloma.

Dr. Bekaii-Saab Compares Toxicities of Regorafenib and TAS-102 in Colorectal Cancer

November 22nd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, compares the toxicity profiles of regorafenib and TAS-102, which are both used to treat patients with metastatic colorectal cancer.

Dr. Robert Dreicer on Overcoming Resistance Pathways in mCRPC

November 21st 2016

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses next-generation antiandrogen therapies in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Tripathy on Immunotherapy Potential in HER2-Positive Breast Cancer

November 19th 2016

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy in the treatment of patients with HER2-positive breast cancer.

Dr. Stein on Circulating Biomarkers in Prostate Cancer

November 19th 2016

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the use of novel circulating biomarkers in the treatment of patients with prostate cancer.

Dr. Morris on Novel Approaches With Radium-223 in mCRPC

November 18th 2016

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses what novel combinatorial approaches researchers will be explored with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Kantoff on Evolving Role of Docetaxel in Prostate Cancer Treatment

November 18th 2016

Philip W. Kantoff, MD, chairman of Medicine at Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care winner for Genitourinary Cancer, discusses the role that chemotherapy treatment with docetaxel will continue to have in patients with prostate cancer. Kantoff shared this insight in an interview during the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Dr. Scher on Predicting Sensitivity to Treatment for mCRPC

November 18th 2016

Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses understanding the genetics of patients with metastatic castration-resistant prostate cancer.

Dr. Iyer on Advice for Physicians Using Immunotherapy in Bladder Cancer

November 18th 2016

Gopa Iyer, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses significant points for community oncologists to be aware of when treating patients with bladder cancer with immunotherapy agents.

Dr. Kris on Sequencing Challenges in Lung Cancer

November 17th 2016

Mark G. Kris, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses challenges associated with sequencing in the treatment of patients with lung cancer.

Dr. Borgen on Successful Progress in HER2-Positive Breast Cancer

November 17th 2016

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses the successful progress seen in the treatment landscape of HER2-positive breast cancer.

Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLC

November 17th 2016

Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.

Dr. Suzanne L. Topalian on Immunotherapy Biomarkers in CRC

November 17th 2016

Suzanne L. Topalian, MD, professor of Surgery, Johns Hopkins Medicine, discuses novel immunotherapy biomarkers in colorectal cancer (CRC).

Dr. Goldberg on PD-L1 as a Biomarker in Lung Cancer

November 17th 2016

Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses the use of PD-L1 as a biomarker in treating patients with lung cancer.

Susan Lutgendorf on Impact of Minimal Support on Patients With Ovarian Cancer

November 16th 2016

Susan Lutgendorf, PhD, professor and Starch Faculty Fellow, Psychological and Brain Sciences, College of Liberal Arts and Sciences, University of Iowa, discusses the impact of lack of support on patients with ovarian cancer. Lutgendorf spoke on this during an interview at the SITC 31st Annual Meeting and Associated Programs.

Dr. Borghaei on the Management of Immune-Related Side Effects in Lung Cancer

November 16th 2016

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the management of slightly rarer side effects that patients with lung cancer can experience when treated with immunotherapy agents.

Lisa Butterfield on SITC Immune Biomarkers Task Force

November 16th 2016

Lisa Butterfield, PhD, professor of Medicine, Surgery and Immunology, director, University of Pittsburgh Cancer Institute Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, discusses the goals of the Society for Immunotherapy of Cancer (SITC) Immune Biomarkers Task Force during an interview at the SITC 31st Annual Meeting and Associated Programs.